News Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
3.49 ^USD	-0.29%		-4.51%	+33.72%

Apr. 11	Summit Therapeutics Inc. Appoints Dr. Mostafa Ronaghi to Its Board of Directors	CI
Apr. 09	Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed	RE

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors	Apr. 11	BU
Summit Therapeutics Inc. Appoints Dr. Mostafa Ronaghi to Its Board of Directors	Apr. 11	CI
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum	Apr. 10	BU
Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed	Apr. 09	RE
Illumina Names Ankur Dhingra as Chief Financial Officer	Apr. 09	MT
Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor	Apr. 09	RE
Summit Therapeutics Appoints COO to Additional Role of CFO	Apr. 04	MT
Summit Therapeutics Inc. Announces Chief Financial Officer Changes	Apr. 03	CI
Summit Therapeutics Inc. Appoints Bhaskar Anand as Chief Accounting Officer, Head of Finance, to Serve as Its Principal Accounting Officer	Apr. 03	CI
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	Apr. 01	MT
Summit Therapeutics Insider Bought Shares Worth $375,000, According to a Recent SEC Filing	Mar. 28	MT
Stifel Initiates Summit Therapeutics With Buy Rating, $8 Price Target	Mar. 26	MT
Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	Mar. 25	AQ
Summit Therapeutics Reports 23% Complete Response in Metastatic NSCL Cancer Drug Ivonescimab's Clinical Trials	Mar. 22	MT
Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	Mar. 22	BU
Summit Therapeutics Inc. Announces Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	Mar. 22	CI
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast	Mar. 18	MT
Summit Therapeutics Inc.(NasdaqGM:SMMT) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024	Mar. 14	BU
Summit Therapeutics Inc. Announces That Data for Its Novel, Potential First-In-Class Investigational Bispecific Antibody, Ivonescimab, Will Be Presented At the 2024 European Lung Cancer Congress (Elcc 2024) in Prague, Czech Republic	Mar. 14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Summary

Filters